Construction and immunogenicity of a trypsin-independent porcine epidemic diarrhea virus variant

Front Immunol. 2023 Mar 24:14:1165606. doi: 10.3389/fimmu.2023.1165606. eCollection 2023.

Abstract

Porcine epidemic diarrhea virus (PEDV) is a re-emerging enteropathogenic coronavirus that causes high mortality in neonatal piglets. The addition of trypsin plays a crucial role in the propagation of PEDV, but also increases the complexity of vaccine production and increases its cost. Previous studies have suggested that the S2' site and Y976/977 of the PEDV spike (S) protein might be the determinants of PEDV trypsin independence. In this study, to achieve a recombinant trypsin-independent PEDV strain, we used trypsin-dependent genotype 2 (G2) PEDV variant AJ1102 to generate three recombinant PEDVs with mutations in S (S2' site R894G and/or Y976H). The three recombinant PEDVs were still trypsin dependent, suggesting that the S2' site R894 and Y976 of AJ1102 S are not key sites for PEDV trypsin dependence. Therefore, we used AJ1102 and the classical trypsin-independent genotype 1 (G1) PEDV strain JS2008 to generate a recombinant PEDV carrying a chimeric S protein, and successfully obtained trypsin-independent PEDV strain rAJ1102-S2'JS2008, in which the S2 (amino acids 894-1386) domain was replaced with the corresponding JS2008 sequence. Importantly, immunization with rAJ1102-S2'JS2008 induced neutralizing antibodies against both AJ1102 and JS2008. Collectively, these results suggest that rAJ1102-S2'JS2008 is a novel vaccine candidate with significant advantages, including no trypsin requirement for viral propagation to high titers and the potential provision of protection for pigs against G1 and G2 PEDV infections.

Keywords: chimeric virus; immunogenicity; neutralizing antibodies; porcine epidemic diarrhea virus (PEDV); trypsin-independent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / genetics
  • Mutation
  • Porcine epidemic diarrhea virus* / genetics
  • Swine
  • Swine Diseases* / prevention & control
  • Viral Vaccines* / genetics

Substances

  • Viral Vaccines
  • Antibodies, Neutralizing

Grants and funding

This work is supported by the National Key Research and Development Program of China (2022YFD1800801 and 2022YFD1800803).